Over 60 companies across the globe claim to manufacture drug products / drug
The COVID-19 pandemichas severely impaired the overall pharmaceutical supply chain, mostly owing tothe absence of workers at manufacturing sites and restrictions imposed ondistribution networks. In this context, continuous manufacturing offers a viablesolution given the fact that continuous processes are largely automated. Infact, the FDA (and other regulatory bodies) have also expressed interest inadvocating a shift to the use of advanced manufacturing technologies, such ascontinuous manufacturing.
To order this 310+ page report, which features 110+ figuresand 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html
TheUSD 1.9 billion (by 2030) financial opportunity within the continuousmanufacturing market has been analyzed across the following segments:
§ Purposeof Manufacturing
§ In-House
§ Contract service
§ Scaleof Operation
§ Commercial
§ Preclinical /Clinical
§ Typeof Continuous Manufacturing related Service
§ APIManufacturing
§ EndProduct manufacturing
§ Typeof Drug Molecule
§ Biologic
§ Small Molecule
§ Typeof dosage form
§ Solid
§ Liquid
§ KeyGeographical Regions
§ North America
§ Europe
§ Asia Pacific
The ContinuousManufacturing Market (Small Molecules and Biologics), 2020 – 2030 reportfeatures the following companies, which we identified to be key players in thisdomain:
§ AbbVie ContractManufacturing
§ Ajinomoto Bio-PharmaServices
§ Almac
§ Boehringer IngelheimBioXcellence
§ Cambrex
§ CordonPharma
§ Hovione
§ Kaneka
§ Lonza
§ Patheon
§ SK biotek
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape
5. Companies with Expertise in ContinuousManufacturing in North America: Profiles
6. Companies with Expertise in ContinuousManufacturing in Europe: Profiles
7. Companies with Expertise in ContinuousManufacturing in Asia-Pacific: Profiles
8. Recent Partnerships and Collaborations
9. Recent Expansions
10. Capacity Analysis
11. Academic Grant Analysis
12. Patent Analysis
13. Initiatives of Companies with In-HouseContinuous Manufacturing Capabilities
14. Case Study: Modular Facilities inpharmaceutical / Biotechnological Industry
15. Case Study: Technology and EquipmentProviders
16. Case Study: Roadmap for the Adoption ofContinuous Manufacturing Processes
17. Market Forecast and Opportunity Analysis
18. Conclusion
19. Executive Insights
20. Appendix1: Tabulated Data
21. Appendix2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
